Tag: Antibody-Drug-Conjugate
IDT Australia receives grant to establish first commercial ADC manufacturing hub
IDT Australia Limited announced its successful bid for a Victoria State Government grant worth $3.8 million to support the creation of Australia’s inaugural cGMP Antibody-Drug-Conjugate (ADC) manufacturing facility.
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
